Effect of apatinib mesylate combined with docetaxel in the second-line treatment of advanced gastric cancer and its influences on peripheral blood tumor abnormal protein,vascular endothelial growth factor and matrix metalloproteinase-9
Objective To investigate the effect of apatinib mesylate combined with docetaxel in the second-line treatment of advanced gastric cancer and its influences on peripheral blood tumor abnormal protein,vascular endothelial growth factor(VEGF)and matrix metalloproteinase-9(MMP-9).Methods A total of 90 patients with advanced gastric cancer admitted from March 2020 to March 2022 were selected as the study subjects,and the patients were randomly divided into control group and observation group,with 45 cases in each group.The control group was treated with docetaxel chemotherapy regimen,and the observation group was treated with apatinib mesylate on the basis of the control group.The therapeutic effects of the two groups were compared.Results The disease control rate of the observation group was higher than that of the control group(P＜0.05).After treatment,the levels of carbohydrate antigen 19-9(CA19-9),tumor supplied group of factors(TSGF)and carcinoembryonic antigen(CEA)in the observation group were lower than those in the control group(P＜0.05).After treatment,the levels of VEGF,MMP-9,tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in the observation group were lower than those in the control group(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Apatinib mesylate combined with docetaxel in the second-line treatment of advanced gastric cancer has better effect,it can inhibit the peripheral blood tumor abnormal protein,and regulate the levels of VEGF and MMP-9,and does not increase the risk of adverse reactions,which is worthy of application and promotion.
NETL
NSTL
万方数据
